Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Innovation
Share your love
Throwback Series: Managing bilateral diabetic macular edema early in practice | Ophthalmology Times
In celebration of Ophthalmology Times’ 50th anniversary, leaders revisit a memorable “throwback” case from earlier in their careers. In this special series, they reflect on how evolving knowledge, techniques, and technologies have transformed the way such cases are managed today.…
Throwback Series: When tools of the past teach new lessons | Ophthalmology Times
In celebration of Ophthalmology Times’ 50th anniversary, leaders revisit a memorable “throwback” case from earlier in their careers. In this special series, they reflect on how evolving knowledge, techniques, and technologies have transformed the way such cases are managed today.…
FDA issues Complete Response Letter to Sydnexis for SYD-101 pediatric myopia treatment | Ophthalmology Times
The FDA has requested additional evidence for Sydnexis’ SYD-101, a 0.01% atropine eye drop aimed at slowing myopia progression in children, despite positive outcomes from the STAR clinical trial. (Image credit: Ophthalmology Times) The FDA has sent a complete response…
Periorbital rejuvenation: Past, present, and next | Ophthalmology Times
(Image Credit: AdobeStock/Alessandro Grandini) The aesthetic treatment of the periorbital region has evolved significantly, shaped by centuries of innovation and driven by the desire to understand anatomy and how it is affected by aging. Among the earliest documented advancements in…
AAO 2025: Glaucoma laser surgery with Joel S. Schuman, MD, FACS | Ophthalmology Times
Joel S. Schuman, MD, FACS, of Wills Eye Hospital, presented an update on laser therapies for glaucoma, emphasizing recent innovations in selective laser trabeculoplasty (SLT) and laser cyclophotocoagulation at the American Academy of Ophthalmology 2025 annual meeting, October 18 to…
Charles Miller, MD, PhD, on DME research and the initiation of the phase 2b/3 BRUNELLO trial | Ophthalmology Times
Image credit: AdobeStock/MrAshi On September 4, 2025, Merck and EyeBio announced that the companies have initiated the Phase 2b/3 BRUNELLO trial (NCT06571045) to evaluate the candidate MK-3000, formerly known as EYE103 for the treatment of patients with diabetic macular edema…
Q&A: Frank Holz shares how innovation showcased at EURETINA brings hope for patients with GA | Ophthalmology Times
Photo of Frank Holz at the 2025 EURETINA meeting Frank Holz, MD, FEBO, FARVO, a retina specialist from Bonn, Germany, discusses the EURETINA meeting, highlighting groundbreaking advancements in retinal disease treatments. With a record attendance of over 11,000, the conference…
Q&A: Mario Romano discusses temperature during vitrectomy | Ophthalmology Times
Photo of Mario Romano at EURETINA 2025 Mario Romano, MD, PhD, a researcher from Humanitas University in Italy, discusses work on temperature control during vitrectomy. His research, supported by the Italian Ministry of Research, reveals significant temperature drops during eye…
Anniversary of the spectral OCT prototype: 25 years young and growing | Ophthalmology Times
A recent conference celebrated the creation of the first prototype of the spectral optical coherence tomography (SOCT) instrument. Introduced in 2000, the prototype, which was developed at the Institute of Physics of Nicolaus Copernicus University in Toruń, Poland, was the…
Conavi Medical submits Novasight Hybrid IVUS/OCT System to FDA for 510(k) clearance | Ophthalmology Times
(Image Credit: AdobeStock/gguy) Conavi Medical has submitted its Novasight Hybrid™ IVUS/OCT intravascular imaging system to the US Food and Drug Administration (FDA) for 510(k) clearance for coronary applications. While optical coherence tomography (OCT) is traditionally used to monitor retinal diseases,…